medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2020, Number 1

<< Back Next >>

Rev Mex Med Transfus 2020; 13 (1)

Evaluation and management of platelet refractoriness: a proposal

Calderón GA, Graciano VN

Language: Spanish
References: 42
Page: 7-14
PDF size: 175.56 Kb.


ABSTRACT

Introduction: Refractoriness to platelet transfusion therapy can be defined as post-transfusion platelet increment that is less than expected, platelet refractoriness occurs in 27% of patients who undergo a platelet transfusion, constituting a limitation when transfusing a patient with this condition. Objective: Design a pragmatic approach to the evaluation and management of patients with platelet refractoriness. We present an algorithm for their management. Material and methods: The authors conducted a search of references of recent articles addressing the subject of interest in the database MEDLINE, through PubMed. Conclusions: The management of platelet refractoriness begins with the prevention of sensitization. To date there is no method to diagnose refractoriness of non-immune origin, in many cases it can coexist with some degree of immune refractoriness.


REFERENCES

  1. Fasano R, Josephson C. Platelet transfusion goals in oncology patients. Hematology. 2015; 2015: 462-470. doi: 10.1182/asheducation-2015.1.462.

  2. Gibson BE, Todd A, Roberts I et al. Transfusion guidelines for neonates and older children. Br J Haematol. 2004; 124 (4): 433-453. doi: 10.1111/j.1365-2141.2004.04815.x.

  3. Wandt H, Ehninger G, Gallmeier W. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist. 2001; 6 (5): 446-450. doi: 10.1634/theoncologist.6-5-446.

  4. Phekoo K, Hambley H, Schey S, Win N, Carr R, Murphy M. Audit of practice in platelet refractoriness. Vox Sanguinis. 1997; 73 (2): 81-86. doi: 10.1046/j.1423-0410.1997.7320081.x. 

  5. The Trial to Reduce Alloimmunization To Platelets Study Group. Leukocyte reduction and utraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337 (26): 1861-1869.

  6. Slicther S, Davis K, Enright H, Braine H, Gernshimer T, Kao K et al. Factors affecting post-transfusion platelets increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005; 105 (10): 4106-4114. doi: 10.1182/blood-2003-08-2724.

  7. Quillen K. Diagnosis and management of platelet alloimmunization. Column Ask the Hematologist. Hematology. 2013; 10 (6): 1023.

  8. Daly A, Hasegawa W, Lipton J, Messner H, Kiss T. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and veno-occlusive disease of the liver. Transfus Apher Sci. 2002; 27 (1): 3-12.

  9. McCullough J. Overview of platelet transfusion. Semin Hematol. 2010; 47 (3): 235-242. doi: 10.1053/j.seminhematol.2010.04.001.

  10. Novotny V. Prevention and management of platelet transfusion refractoriness. Vox Sang. 1999; 76 (1): 1-13.

  11. Schiffer C, Anderson K, Bennett C, Bernstein S, Elting L, Goldsmith M et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19 (5): 1519-1538.

  12. Pavensky K, Freedman J, Semple J. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012; 79 (4): 237-245. doi: 10.1111/j.1399-0039.2012.01852.x.

  13. Dzik S. How I do it: platelet support for refractory patients. Transfusion. 2007; 47 (3): 374-378. doi: 10.1111/j.1537-2995.2007.01126.x.

  14. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev. 2000; 14 (2): 180-196. doi: 10.1016/s0887-7963(00)80007-3.

  15. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008; 142 (3): 348-360. doi: 10.1111/j.1365-2141.2008.07189.x.

  16. Stanworth S, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015; 171 (3): 297-305. doi: 10.1111/bjh.13597.

  17. Schiffer C. State-of-the-art mini-review. Management of patients refractory to platelet transfusion. Leukemia. 2001; 15 (4): 683-685.

  18. Forest S, Hod E. Management of the platelet refractory patient. Hematol Oncol Clin N Am. 2016; 30 (3): 665-677. doi: 10.1016/j.hoc.2016.01.008.

  19. Valsami S, Dimitroulis D, Gialeraki A, Chimonidou M, Politou M. Current trends in platelet transfusions practice: the role of ABO-RhD and human leukocyte antigen incompatibility. Asian J Transfus Sci. 2015; 9 (2): 117-123. doi: 10.4103/0973-6247.162684.

  20. Kiefel V, König C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Platelet alloantibodies in transfused patients. Transfusion. 2001; 41 (6): 766-770. doi: 10.1046/j.1537-2995.2001.41060766.x.

  21. Panzer S, Auerbach L, Cechova E, Fischer G, Holesteiner A, Kitll E et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol. 1995; 90 (3): 655-660.

  22. Kurz M, Greinix H, Cker P, Kalhs P, Kno P, Mayr W et al. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol. 1996; 95 (3): 564-569. doi: 10.1046/j.1365-2141.1996.d01-1936.x.

  23. Dutcher J, Schiffer C, Aisner J, Wiernik P. Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood. 1981; 59 (5): 1007-1011.

  24. Seftel M, Growe G, Petraszko T, Barret B, Le A, Lee C et al. Universal leukorecution in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004; 103 (1): 333-339. doi: 10.1182/blood-2003-03-0940.

  25. Heddle N, Arnold D, Boye D, Webert K, Resz I, Dumont L. Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review. Transfusion. 2008; 48 (7): 1447-1458. doi: 10.1111/j.1537-2995.2008.01731.x.

  26. Vasallo R, Fung M, Rebulla P, Duquesnoy R, Saw C, Slichter S. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion. 2014; 54 (4): 1180-1191. doi: 10.1111/trf.12395.

  27. Rebulla P, Morelati F, Revelli N, Villa M, Paccapelo C, Nocco A. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol. 2004; 125 (1): 83-89.

  28. Kopko P, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune-refractory patients.Transfusion. 2015; 55 (2): 235-244. doi: 10.1111/trf.12921.

  29. Kalmadi S, Tiu R, Lowe C. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006; 107 (1): 136-140.

  30. Antun A, Gleason S, Arellano M. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013; 119 (21): 3784-3787.

  31. Ratko T, Burnett D, Foulke G. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA. 1995; 273 (23): 1865-1870.

  32. Schiffer C, Hogge D, Aisner J. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood. 1984; 64 (4): 937-940.

  33. Hogge D, Dutcher J, Aisner J. The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients. Blood. 1984; 64 (1): 253-256.

  34. Heddle N, Klama L, Kelton J. The use of anti-D to improve posttransfusion platelet response: a randomized trial. Br J Haematol. 1995; 89 (1): 163-168.

  35. Muńiz E, Martínez C, Madoz P. Refractariedad a las transfusiones de plaquetas. Med Clin. 2003; 120 (14): 544-549.

  36. Christie D, Howe R, Lennon S, Sauro S. Treatment of refractoriness to platelet transfusion by protein A column therapy. Trans. 1993; 33 (3): 234-242.

  37. Nagasawa T, Kim B, Baldini M. Temporary suppression of circulating antiplatelet alloantibodies by the massive infusion of fresh, stored, or lyophilized platelets. Trans. 1978; 18 (4): 429-435.

  38. Friedmann A, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002; 16 (1): 34-45.

  39. Lee E, Schiffer C. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusion in alloimmunized patients. Blood. 1987; 70 (6): 1727-1729.

  40. Narvios A, Reddy V, Martinez F. Slow infusion of platelets: a possible alternative in the management of refractory thrombocytopenic patients. Am J Hematol. 2005; 79 (1): 80.

  41. Heuer L, Blumenberg D. Management of bleeding in a multitransfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinol. 2005; 16 (4): 287-290.

  42. Vidarsson B, Onundarson P. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000; 83 (4): 634-635.




2020     |     www.medigraphic.com